Skip to main content
. 2020 Sep 22;20(4):319–330. doi: 10.1007/s40268-020-00320-5

Fig. 3.

Fig. 3

Ratio of total cases (monoclonal antibody-induced SCLE) against the annual estimated monoclonal antibody users as a percentage. Therapies utilising anti-tumour necrosis factor-ɑ mechanisms are highlighted in yellow and anti-PD-1 drugs are shown in orange. SCLE subacute cutaneous lupus erythematosus, PD-1 programmed cell death-1